试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
编号:NCT02740699登记状态:提前终止企业 / 申办者:National Heart, Lung, and Blood Institute (NHLBI)
药物 / 成分:Rosuvastatin、Atorvastatin、Cardiac Computed Tomography (CT)、Cardiac Magnetic Resonance Image (MRI)
登记的停止原因(原文):Principal Investigator resigned and closed program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
编号:NCT03201445登记状态:提前终止企业 / 申办者:Lakefront Biotherapeutics NV
药物 / 成分:Filgotinib、Placebo、Standard of Care
登记的停止原因(原文):Early Termination for Reasons other than Safety
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
编号:NCT03203850登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Deferasirox FCT、Phlebotomy
登记的停止原因(原文):Due to enrolment challenge
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
编号:NCT03207867登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:NIR178、PDR001
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
编号:NCT03447769登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Canakinumab、Placebo
登记的停止原因(原文):Upon review of the primary analysis results, the benefit-risk was assessed by the Steering Committee Members with the decision that the study will be closed. No new safety signals were observed for canakinumab.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
编号:NCT03452137登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Atezolizumab、Placebo
登记的停止原因(原文):Decision to terminate the study as its primary endpoint of investigator-assessed event free survival (INV-EFS) was not met at its final EFS analysis. No new safety signals were identified.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
编号:NCT04139317登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Capmatinib、Pembrolizumab
登记的停止原因(原文):Sponsor decision to terminate due to the lack of tolerability observed in patients treated with capmatinib and pembrolizumab in the combination arm as compared to patients treated with pembrolizumab alone in the pembrolizumab single agent arm
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
编号:NCT04154787登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:LNP023、Rituximab
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
编号:NCT04323436登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Spartalizumab、Capmatinib、spartalizumab placebo
登记的停止原因(原文):Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-09
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
编号:NCT04428333登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Feladilimab、Pembrolizumab、Placebo、Platinum based chemotherapy
登记的停止原因(原文):The trial was stopped by the sponsor based on assessment of the clinical data
查看官方原始记录 ↗